Multiple Sclerosis Drug Therapy

interferon beta 1a (Avonex), interferon beta 1b (Betaseron, Extavia), interferon beta 1a (Rebif, Rebif Rebidose), glatiramer (Copaxone, Glatopa), peginterferon beta 1a (Plegridy)

SELF ADMINISTRATION

Indications for Prior Authorization:

  • Relapsing remitting multiple sclerosis (RRMS)
  • Secondary progressive multiple sclerosis (SPMS)

Avonex, Betaseron, Copaxone 40mg, Glatopa, Plegridy and Rebif are preferred disease modifying agents for the treatment of multiple sclerosis when all the criteria below are met.

Patients must meet the following criteria for the indications above:

  • Diagnosis confirmed by a neurologist, AND
  • None of these drugs may be used in combination with each other or any other disease-modifying therapy including natalizumab (Tysabri), mitoxantrone (Novantrone), alemtuzumab or fingolimod (Gilenya)
  • Any condition not listed above does not meet WHA criteria for approval

Dosing:

  • interferon beta 1a (Avonex) - up to 30 mcg IM once per week
  • interferon beta 1b (Betaseron, Extavia) - up to 0.25 mg SC every other day
  • interferon beta 1a (Rebif, Rebif Rebidose) - up to 44 mcg SC three times per week
  • glatiramer (Copaxone, Glatopa) - 20 mg SC daily OR 40 mg 3 times per week
  • peginterferon (Plegridy) - maintenance: 125 mcg SC every 14 days

Approval:

  • Initial approval for one year
  • Renew for one year if patient has clinical response

 


 

Last review date: December 1, 2014

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.

Press Esc to cancel

El sitio Web al que está siendo transferido no es provisto por WHA. Las Condiciones de Uso y las Prácticas de Privacidad en Internet de WHA no se aplican a este sitio Web asociado que usted está usando. Revise las políticas sobre la privacidad y condiciones de uso de este sitio Web asociado. WHA no tiene control sobre la exactitud, la totalidad o la actualidad del contenido del sitio Web asociado. WHA no puede garantizar que los servicios de traducción de idiomas estarán disponibles en el sitio vinculado.

Presione «Esc» para cancelar